Breast Cancer Res Treat. 2017 Jun 23. doi: 10.1007/s10549-017-4338-x. [Epub ahead of print]
Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy?
Partridge AH1,2, Sepucha K3,4, O'Neill A5, Miller KD6, Baker E5, Dang CT7, Northfelt DW8, Sledge GW6,9, Schneider BP6.
Information about a positive biomarker indicating increased benefit and toxicity from additional chemotherapy did not change many participants' preferred treatment. The majority preferred the most effective course in both scenarios. Similarly, most investigators discounted increased toxicity and valued increased benefit. Parent Trial Registration: NCT00433511.
Adjuvant therapy; Biomarkers; Breast cancer; Patient preferences; Risk; Toxicity